Only one biopharma group is actively trialing a GLP-1 agonist in the condition. It might not be alone for long.

Just over six months after getting a complete response letter for its prodrug carbidopa and levodopa combination product, the US major has acquired Mitokinin and its selective PINK1 activator which could potentially be a disease-modifying treatment for Parkinson’s disease.

The US firm’s lead program has flunked a mid-stage trial in early Parkinson’s disease and, despite a promising efficacy signal in a younger patient cohort, its future remains uncertain.

In Vivo takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.